Evidence map›Paper›PMID 41565699›Full record

ArticleNature communications2026

ZNF683

Guo Li, Wenhao Xiao, Haijun Wu, Chao Liu, Liang Gong, Haoyu Zhang, Zhuo Shao, Jing Bai, Xuefeng Xia, Xin Yi and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. From iPSC to manufactured iNK cells using CombiCult® screening platform.Frontiers in cell and developmental biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Guo Li *Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0001-7646-4213
Wenhao Xiao *Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Haijun Wu *Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Chao LiuDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Liang GongDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Haoyu ZhangDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhuo ShaoGenomics Institute, Geneplus-Beijing, Beijing, China.
Jing BaiGenomics Institute, Geneplus-Beijing, Beijing, China.
Xuefeng XiaGenomics Institute, Geneplus-Beijing, Beijing, China.
Xin YiGenomics Institute, Geneplus-Beijing, Beijing, China.
Yunyun WangDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Shanhong LuDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Li SheDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Juncheng WangDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0002-1163-7707
Gangcai ZhuDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiaojuan ZhouDepartment of Otolaryngology Head and Neck Surgery, Xiangya Third Hospital, Central South University, Changsha, Hunan, China.
Wenmei WangDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Liangfang ShenDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Nu ZhangDepartment of Microbiology, Immunology and Molecular Genetics, Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID 0000-0001-9695-210X
Xingwei WangDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Donghai HuangDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Junwei HouDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0001-6588-9785
Yuanzheng QiuDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xin ZhangDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. xinzhang@csu.edu.cn.
Mien-Chie HungGraduate Institute of Biomedical Sciences, China Medical University, Taiwan, China. mhung@cmu.edu.tw.ORCID 0000-0003-4317-4740
Yong LiuDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. liuyongent@csu.edu.cn.ORCID 0000-0001-5102-0309

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82073009National Natural Science Foundation of China (National Science Foundation of China) 82103631National Natural Science Foundation of China (National Science Foundation of China) 82173341National Natural Science Foundation of China (National Science Foundation of China) 82301286National Natural Science Foundation of China (National Science Foundation of China) 82303717National Natural Science Foundation of China (National Science Foundation of China) 82303946
6 · The paper itself

Abstract

Hypopharyngeal squamous cell carcinoma (HPSCC), an aggressive head and neck cancer with dismal prognosis, faces persistent chemoresistance to standard TPF (docetaxel, cisplatin, 5-fluorouracil) regimen. However, the immunological mechanisms underlying chemoresistance remain undefined. Here, we perform longitudinal single-cell RNA sequencing (scRNA-seq) profiling of paired pre-/post-TPF HPSCC specimens, mapping immune cell dynamics underlying chemoresistance. Our study identifies ZNF683

Indexed as

DNA-Binding ProteinsDrug Resistance, NeoplasmHead and Neck NeoplasmsKiller Cells, NaturalSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentAntineoplastic Combined Chemotherapy ProtocolsCD8-Positive T-LymphocytesCell Line, TumorCisplatinDocetaxelFemaleFluorouracilHumansMemory T CellsSingle-Cell AnalysisCisplatinDNA-Binding ProteinsDocetaxelFluorouracil

Identifiers

PMID41565699
PMCPMC12949071

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.